Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CKD-386 vs Co-administered Components in Healthy Volunteers
NCT04673864Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Jan 2021; status: completed.
02
Drugs
telmisartanrosuvastatinezetimibe
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04673864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673864.